The Global Genetic Testing Market accounted for $3.2 billion in 2014 and is expected to grow at a CAGR of 9.26% to reach $6.5 billion by 2022. The factors contributing to the market growth include aging population, growing awareness, availability of direct to consumer tests and increasing incidence of genetic disorders. However, factors such as high cost for testing and reimbursement issues are inhibiting the growth of the market.
Genetic testing is the most profitable and rapidly expanding segment of molecular diagnostics. It is the array of techniques used for the analysis of DNA, RNA, and protein. It is used as a medical tool to determine the genetic defects associated with a particular disease. Genetic testing is also used in non-clinical applications such as paternity testing and forensics.
In clinical applications, the primary focus of genetic testing is to identify the genetic reason for the cause of a disease, confirm a suspected diagnosis, prediction of future disease, to identify when an individual may pass his/her hereditary information to kids, and to predict treatment response in a patient. Genetic testing is also used to screen new-born babies, fetuses, or embryos used in-vitro fertilization for genetic defects.
The genetic testing market is categorized based on its applications into pharmacogenomics testing, predictive testing, prenatal and neonatal testing. Genetic testing for cancer is likely to be the fastest growing segment during the forecast period. Increasing incidence of genetic diseases is providing more opportunities for genetic testing along with the rise in personalized medicine. The federal agencies who play a significant role in regulating genetic tests are Food and Drug Administration (FDA), Federal Trade Commission (FTC) and Center for Medicare and Medicaid services (CMS).